AML patients with mutated IKZF1 was usually associated with aberration in RUNX1, GATA2, KRAS, KIT, SF3B1, and ETV6. IKZF1 mutation could be an independent marker of adverse risk regarding complete remission rate, event-free, relapse-free, and overall survival (101). This evidence concerns the gene SF3B1 and acute myeloid leukemia.